Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Incyte pancreatic cancer drug shows lasting tumor responses at ESMO

Incyte says its targeted pancreatic cancer drug, paired with chemotherapy, produced lasting tumor responses in selected patients at ESMO.

A phase 3 Merck and Kelun-Biotech ADC trial cut death risk by one-third in advanced endometrial cancer, signaling…

PSMA-PET detected recurrence in 55% after prostatectomy, with PSA and age predicting positivity and pathologic features linked to…

GBD 2023 estimates show rising breast cancer incidence and mortality in low-income countries, with 2050 forecasts pointing to…

Risk attribution modeling linked Helicobacter pylori exposure to an estimated 22% of colorectal cancer cases globally, with stronger…

Tumor-derived IL-6 rewires intrahepatic cholangiocarcinoma cells, alters immune behavior, and exposes a metabolic vulnerability to NAMPT inhibition.

FDA approves talazoparib plus enzalutamide for metastatic HRR-mutated prostate cancer after TALAPRO-3 showed a major rPFS gain.

Updated prescribing information for pirtobrutinib adds CLL/SLL indications and details dosing, drug interactions, and key safety monitoring.

DailyMed’s leucovorin label details methotrexate rescue, folate deficiency treatment, and its potentiation of 5-FU in advanced colorectal cancer.

Human embryonic stem cell modeling suggests RUNX1-ETO dosage may steer AML cells between endothelial reprogramming and pre-leukemic expansion.

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds